Temporal Trends and Clinical Characteristics of Incretin‐Based Therapy Use in Women With Polycystic Ovary Syndrome: A Real‐World Cohort Study From a Polish Private Healthcare Network
Authors' conclusion
Incretin-based therapy use in PCOS increased markedly over time, suggesting expansion beyond classical glycaemic indications toward weight-focused and cardiometabolic management.
Study context
- Population
- Adult women with ICD-coded polycystic ovary syndrome (PCOS), LUX MED network, Poland, EHR data July 2006 to April 2026; primary analysis: PCOS diagnosed 2018–2024
- Participants
- 38,263 women
- Exposure
- GLP-1 RA/GIP-GLP-1 RA users vs Metformin-only vs Untreated
- GLP-1 RA/GIP-GLP-1 RA usersn = 4,557
- Outcome
- Prescription-recorded initiation of GLP-1 RA/GIP-GLP-1 RA therapy after index diagnosis, temporal trend by calendar year
- Follow-up
- Within 365 days
Methodological detailselectronic health records, private healthcare network
- Electronic health records
- Private healthcare network
Main finding
As reported in the abstract
Initiation of GLP-1 RA/GIP-GLP-1 RA within 365 days
Calendar year (per year)Estimate (95% CI)P value
Initiation of GLP-1 RA/GIP-GLP-1 RA within 365 days
unadjusted OR 1.52(1.44–1.59)
P < 0.001Multivariable-adjusted
adjusted OR 1.64(1.56–1.73)
P < 0.001Per year, as printed
- Initiation in 2018
- 0.14%
- Initiation in 2024
- 5.97%
Observational data: associations, not effects.
Further findings
Recorded BMI — GLP-1 RA/GIP-GLP-1 RA users vs Metformin-only or untreated
all p < 0.001
Overall prescription use
- Recorded GLP-1 RA/GIP-GLP-1 RA prescription
- 4557 (11.9%)
- Received metformin
- 16 381 (42.8%)
Characteristics of incretin-based therapy users
- Metformin co-exposure
- 75.5%
- Coded T2D
- 11.5%
Recorded BMI
- Greater comorbidity burden in GLP-1 RA/GIP-GLP-1 RA users
Original publication
Temporal Trends and Clinical Characteristics of Incretin‐Based Therapy Use in Women With Polycystic Ovary Syndrome: A Real‐World Cohort Study From a Polish Private Healthcare Network. Diabetes Obes Metab. Published 15 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →